醫療是公共服務不是商業買賣，請刪除服務貿易協議醫療條文
版主: 版主021
-
tsmc
- V2
- 文章: 2415
- 註冊時間: 週一 5月 04, 2009 3:15 pm
-
李誠民
- 註冊會員
- 文章: 1467
- 註冊時間: 週三 6月 23, 2010 10:18 am
Re: 醫療是公共服務不是商業買賣，請刪除服務貿易協議醫療條文
很可惜, 沒能參加您的"專題演講"(?), 您所指的大陸法令, 我一直有在收集,;服貿對醫療行業, 是集部對等的;大陸是要台灣資金,人才?(有名望的!!!); 只因醫療事業是服務業也好,; 但絕不是托拉斯的(純商業!!)的財團企業; 台灣長庚體系, 就是好例子!!!......典型官商勾結的醫療體系(---商逼官改革!!!)......不會玩Blog, 對不起!!!
-
李誠民
- 註冊會員
- 文章: 1467
- 註冊時間: 週三 6月 23, 2010 10:18 am
Re: 醫療是公共服務不是商業買賣，請刪除服務貿易協議醫療條文
今天媒體報導:有網民發動到美國白宮"請願";....台灣是美國的一州嗎?!....
現在是提倡"區域經貿協議",--從歐盟(European Union)三 十多年成立,對WTO(World Trade Organization, 屬聯合國組織--United Nation,長久是被美國操控的!!!......); 下面個人舉個例子, 來說明::
7-Slim(威力纖+):...."Cetilistat has completed Phase 1 and 2 trials in the West and is currently in Phase 3 trials in Japan where it is partnered with Takeda.[4] Norgina BV has now acquired the full global rights to cetilistat from Alizyme after the latter went into administration".....
日本許多藥要申請"專利"(向FDA,US), 就是刁難 阻饒!!!....美國有發言權--霸權心態!!!.....
現在印度 中國大陸是不甩美國的, 因為是人口多, 是世界消費市場,......為甚麼連惠心會冒販售禁藥的危險,強力銷售7-Slim(沒有中國大陸支持?!); 是會冒犯法的危險,.....台灣藥廠超過90%是中國大陸的原料藥(二年前,財訊五月號.....)
葉金川出賣台灣利益,到美國參院作證,甘願讓台灣健保更高成本,Big Pharmacy還可以不販售台灣健保藥,而搶自費藥品市場(獲利更多?!)............
現在是提倡"區域經貿協議",--從歐盟(European Union)三 十多年成立,對WTO(World Trade Organization, 屬聯合國組織--United Nation,長久是被美國操控的!!!......); 下面個人舉個例子, 來說明::
7-Slim(威力纖+):...."Cetilistat has completed Phase 1 and 2 trials in the West and is currently in Phase 3 trials in Japan where it is partnered with Takeda.[4] Norgina BV has now acquired the full global rights to cetilistat from Alizyme after the latter went into administration".....
日本許多藥要申請"專利"(向FDA,US), 就是刁難 阻饒!!!....美國有發言權--霸權心態!!!.....
現在印度 中國大陸是不甩美國的, 因為是人口多, 是世界消費市場,......為甚麼連惠心會冒販售禁藥的危險,強力銷售7-Slim(沒有中國大陸支持?!); 是會冒犯法的危險,.....台灣藥廠超過90%是中國大陸的原料藥(二年前,財訊五月號.....)
葉金川出賣台灣利益,到美國參院作證,甘願讓台灣健保更高成本,Big Pharmacy還可以不販售台灣健保藥,而搶自費藥品市場(獲利更多?!)............
Re: 醫療是公共服務不是商業買賣，請刪除服務貿易協議醫療條文
根據港人研究tsmc 寫:私下調查
資本家 都傾向支持 福懋熱飲
恩 看起來
以商逼統 已經全面成功
資本家一般都會率先支持
但要普羅民眾支持......... 非常耗時
Re: 醫療是公共服務不是商業買賣，請刪除服務貿易協議醫療條文
這段假設是在市場還沒飽和的狀況下，若市場飽和，就是競爭！大量大陸公司進入市場的競爭刺激、分散了台灣中小企業獲利，甚至台灣的中小企業只有體質強的能存活，其餘的倒閉。能來臺的都只是管理階層??不，來的會是勞工(管理階層難道不是勞工??台灣就業機會又少)，因為在飽和的市場競爭下，只有降低成本才能存活、尤其是服務業這種沒有專利的東西，所以他們會化整為零，投資600萬來3人，然後再把資金抽出來，再來3人，因為資金可以流動的，所以這些便宜的中國勞工可就好用！會拉低台灣受雇人的薪資，排擠台灣人的工作機會(倒閉很多中小企業、中國人用自己的人)！就像政府22K政策拉低薪資一樣，這還是最好的狀況。若中國資金看台灣沒什麼好投資的，難道不會投資到房地產??作者忽略了在飽和市場下，只有競爭，企業利潤變薄會幫勞工加薪?? 這是什麼邏輯??天真的想法 (壓力) (壓力) (壓力)服貿開放的是大陸老闆來台灣投資開公司，但是由於能來臺的都只是管理階層，所以真正大量雇用的是台灣的員工。服貿通過之後台灣的理想景象應該會是：到處都是大陸老闆出資的公司，但裡面雇用的是台灣的員工，創造了大量的就業機會，而由於大量大陸公司進入市場的競爭刺激，台灣的本土企業也被迫必須提昇自身提供的員工薪資水準與提供的服務品質才能夠在激烈競爭的市場中存活，這也是對於現在台灣企業的老闆而言這確實是個衝擊的原因。
-
WINDOW
- 指導教授
- 文章: 8219
- 註冊時間: 週三 11月 08, 2006 1:03 pm
Re: 醫療是公共服務不是商業買賣，請刪除服務貿易協議醫療條文
我們的理事長也是資本家喔tsmc 寫:私下調查
資本家 都傾向支持 福懋熱飲
恩 看起來
以商逼統 已經全面成功
刪除服貿協議醫療條文不是要他的命嗎
-
李誠民
- 註冊會員
- 文章: 1467
- 註冊時間: 週三 6月 23, 2010 10:18 am
Re: 醫療是公共服務不是商業買賣，請刪除服務貿易協議醫療條文
"我們的理事長也是資本家喔...?
刪除服貿協議醫療條文不是要他的命嗎.......?"
"反服貿抗議行動決戰今朝，根據平面媒體引述國民黨立委、醫師公會理事長蘇清泉談話，面對佔領國會議場的青年學子與群眾，蘇清泉主張「追究學生破壞議場的賠償與刑責，限期要求學生離開」！不過此番言論，卻遭到前公民1985行動聯盟成員、台大醫師柳醫師怒嗆，「他是醫界最大的恥辱！".....當上立委就昧著良心,當執政黨打手, ...不齒!!!....它是心臟外科醫師, 哪訓練的?!
Patent wars: affordable medicines versus intellectual property rights
BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g1533 (Published 17 February 2014)
Cite this as: BMJ 2014;348:g1533
India’s battle over patents is heating up, with campaigners fighting for access to affordable medicines pitted against the drug industry, which is fiercely protecting its intellectual property rights and profits. Jacqui Wise reports on how action there and in other developing countries is putting the whole patent system under scrutiny監視，監督
The pharmaceutical industry is increasingly looking towards emerging markets, where demand for new drugs is rising rapidly alongside rates of chronic diseas........
Two companies blocked from comparing their generic products to Herceptin in India
BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g1632 (Published 19 February 2014)
Cite this as: BMJ 2014;348:g1632
The drug company Roche has secured an injunction from the High Court of Delhi ordering two pharmaceutical companies—the Bangalore based Biocon and the US based Mylan—not to compare their generic versions of trastuzumab with Roche’s Herceptin.......
Roche and Novartis colluded 勾結﹐串通over wet AMD drugs, says Italian regulator
BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g2006 (Published 10 March 2014)
Cite this as: BMJ 2014;348:g2006
The Swiss drug companies Roche and Novartis have been fined €180m (£150m; $250m) by Italy’s competition authority for allegedly斷言，宣稱 colluding to prevent the use of the cheaper of two drugs in the treatment of wet age related macular degeneration.
The Italian regulator accused the two companies of striking an alliance to prevent the use of Roche’s bevacizumab (which it markets as Avastin) as a treatment for wet age related macular degeneration in favour of the more expensive ranibizumab (Lucentis), made by Novartis.
Both drugs were developed by Genentech, which Roche acquired in 2009, but only Novartis holds the licence to sell ranibizumab outside the United States. Bevacizumab is approved only as a cancer treatment, though both drugs act by inhibiting vascular endothelial growth factor, preventing blood vessel growth.
The report by the Italian Competition Authority said that the difference in price between the drugs was “significant.” Ranibizumab costs about £700 per injection, while bevacizumab costs only about £60 per injection
刪除服貿協議醫療條文不是要他的命嗎.......?"
"反服貿抗議行動決戰今朝，根據平面媒體引述國民黨立委、醫師公會理事長蘇清泉談話，面對佔領國會議場的青年學子與群眾，蘇清泉主張「追究學生破壞議場的賠償與刑責，限期要求學生離開」！不過此番言論，卻遭到前公民1985行動聯盟成員、台大醫師柳醫師怒嗆，「他是醫界最大的恥辱！".....當上立委就昧著良心,當執政黨打手, ...不齒!!!....它是心臟外科醫師, 哪訓練的?!
Patent wars: affordable medicines versus intellectual property rights
BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g1533 (Published 17 February 2014)
Cite this as: BMJ 2014;348:g1533
India’s battle over patents is heating up, with campaigners fighting for access to affordable medicines pitted against the drug industry, which is fiercely protecting its intellectual property rights and profits. Jacqui Wise reports on how action there and in other developing countries is putting the whole patent system under scrutiny監視，監督
The pharmaceutical industry is increasingly looking towards emerging markets, where demand for new drugs is rising rapidly alongside rates of chronic diseas........
Two companies blocked from comparing their generic products to Herceptin in India
BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g1632 (Published 19 February 2014)
Cite this as: BMJ 2014;348:g1632
The drug company Roche has secured an injunction from the High Court of Delhi ordering two pharmaceutical companies—the Bangalore based Biocon and the US based Mylan—not to compare their generic versions of trastuzumab with Roche’s Herceptin.......
Roche and Novartis colluded 勾結﹐串通over wet AMD drugs, says Italian regulator
BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g2006 (Published 10 March 2014)
Cite this as: BMJ 2014;348:g2006
The Swiss drug companies Roche and Novartis have been fined €180m (£150m; $250m) by Italy’s competition authority for allegedly斷言，宣稱 colluding to prevent the use of the cheaper of two drugs in the treatment of wet age related macular degeneration.
The Italian regulator accused the two companies of striking an alliance to prevent the use of Roche’s bevacizumab (which it markets as Avastin) as a treatment for wet age related macular degeneration in favour of the more expensive ranibizumab (Lucentis), made by Novartis.
Both drugs were developed by Genentech, which Roche acquired in 2009, but only Novartis holds the licence to sell ranibizumab outside the United States. Bevacizumab is approved only as a cancer treatment, though both drugs act by inhibiting vascular endothelial growth factor, preventing blood vessel growth.
The report by the Italian Competition Authority said that the difference in price between the drugs was “significant.” Ranibizumab costs about £700 per injection, while bevacizumab costs only about £60 per injection